Synonyms: (-)-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (2R-cis)-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 5-Fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 524W91; BW 1592; BW 524W91; BW-1592; BW-524W91; BW1592; BW524W91; (-)-2'3'-Dideoxy-5-fluoro-3'-thiacytidine; (2R,5S)-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; FTC
Molecular Formula: C8H10FN3O3S
Molecular Weight: 247.25
Linear Structural Formula: C8H10FN3O3S
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: Emtricitabine ((-)-FTC) is an orally active, non-cytotoxic (>100 muM/PBM, CEM, Vero, MT-4), potent nucleoside reverse transcriptase inhibitor (NRTI) against HIV type 1/2 (HIV-1 IC50/culture = 8 nM/PBM (LAV-1), 9 nM/CEM (LAV-1); HIV-2 IC50/culture = 0.7 nM/PBM (ROD2), 100 nM/CEM (Zy)), hepatitis B, as well as simian and feline immunodeficiency viruses. Emtricitabine is activated via 2'-deoxycytidine kinase-mediated phosphorylation to (-)-FTC-5'-triphosphate that inhibits viral reverse transcriptase in a dCTP-competitive manner (HIV-1 Ki = 2.9 muM).